Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Ribociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ribociclib as a study intervention. Browse Ribociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
138
Shown on this page
12
Current sort
Recently updated
Therapy scope
Ribociclib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Ribociclib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 61–72 of 138 matching trials for Ribociclib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

NCT05573555
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Palo Alto, California • San Francisco, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting Early Phase 1 Interventional

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

NCT02933736
View directory record Official record
Conditions
Glioblastoma Multiforme, Meningioma
Interventions
Ribociclib
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 17, 2026, 11:22 AM EDT
Completed No phase listed Observational

A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib

NCT07363434
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ribociclib and Bicalutamide in AR+ TNBC

NCT03090165
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
ribociclib, Bicalutamide
Drug
Lead sponsor
Kari Wisinski
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
6
States / cities
Chicago, Illinois • Lansing, Michigan • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 17, 2026, 11:22 AM EDT
Recruiting Not applicable Interventional

Continuous Versus Intermittent cARdiac Electrical moNitorinG

NCT04336644
View directory record Official record
Conditions
Torsades de Pointe Caused by Drug, Long QT Syndrome
Interventions
BodyGuardian Mini Plus
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ribociclib and Letrozole Treatment in Ovarian Cancer

NCT03673124
View directory record Official record
Conditions
Low Grade Serous Carcinoma
Interventions
Ribociclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
27
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Endocrine therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 17, 2026, 11:22 AM EDT
Recruiting Phase 2 Interventional

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

NCT06409390
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Taxotere, Cytoxan, Trastuzumab deruxtecan, Sacituzumab govitecan, Xeloda, Fulvestrant, Ribociclib, Abemaciclib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 11:22 AM EDT
Terminated Phase 1 Interventional

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT05252416
View directory record Official record
Conditions
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 17, 2026, 11:22 AM EDT
Active, not recruiting No phase listed Observational

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

NCT06495164
View directory record Official record
Conditions
Breast Cancer, Malignant Neoplasm of Breast
Interventions
Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 17, 2026, 11:22 AM EDT

About this Ribociclib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Ribociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ribociclib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Ribociclib.